G Treglia1, S Taralli, A Giordano. 1. Institute of Nuclear Medicine, Department of Bioimages and Radiological Sciences, Catholic University of the Sacred Heart, Rome, Italy. giorgiomednuc@libero.it
Abstract
OBJECTIVE: This study was designed to systematically review the emerging role of whole-body positron emission tomography (PET) with 18F-Fluorodeoxyglucose (FDG) in patients with sarcoidosis. DESIGN: A comprehensive literature search of published studies through December 2010 in PubMed/MEDLINE and Embase databases regarding whole-body FDG-PET and PET/CT in patients with sarcoidosis was performed. RESULTS: Ultimately, we identified nine studies comprising a total of 379 patients with sarcoidosis. Main findings of the included studies are presented. CONCLUSIONS: from this systematic review we can summarize that: (1) positive FDG-PET findings should be interpreted with caution in differentiating sarcoidosis from other inflammatory diseases and malignant abnormalities; (2) FDG-PET seems to be a very useful molecular imaging method in assessing disease activity, in staging and identifying occult sites, and in monitoring treatment response in patients with sarcoidosis; (3) FDG-PET shows a better diagnostic accuracy compared to 67Ga scintigraphy in patients with sarcoidosis, because of a better sensitivity of FDG-PET (mainly due to the high quality of FDG-PET images with superior contrast and spatial resolution compared to 67Ga scintigraphy) in addition to several practical advantages (less radiation exposure, shorter time between injection and imaging).
OBJECTIVE: This study was designed to systematically review the emerging role of whole-body positron emission tomography (PET) with 18F-Fluorodeoxyglucose (FDG) in patients with sarcoidosis. DESIGN: A comprehensive literature search of published studies through December 2010 in PubMed/MEDLINE and Embase databases regarding whole-body FDG-PET and PET/CT in patients with sarcoidosis was performed. RESULTS: Ultimately, we identified nine studies comprising a total of 379 patients with sarcoidosis. Main findings of the included studies are presented. CONCLUSIONS: from this systematic review we can summarize that: (1) positive FDG-PET findings should be interpreted with caution in differentiating sarcoidosis from other inflammatory diseases and malignant abnormalities; (2) FDG-PET seems to be a very useful molecular imaging method in assessing disease activity, in staging and identifying occult sites, and in monitoring treatment response in patients with sarcoidosis; (3) FDG-PET shows a better diagnostic accuracy compared to 67Ga scintigraphy in patients with sarcoidosis, because of a better sensitivity of FDG-PET (mainly due to the high quality of FDG-PET images with superior contrast and spatial resolution compared to 67Ga scintigraphy) in addition to several practical advantages (less radiation exposure, shorter time between injection and imaging).
Authors: F B van Hoeij; R G M Keijsers; B C A J Loffeld; G Dun; P H G M Stadhouders; B L A M Weusten Journal: Eur J Nucl Med Mol Imaging Date: 2014-08-20 Impact factor: 9.236
Authors: Rémy L M Mostard; Sander M J Van Kuijk; Johny A Verschakelen; Marinus J P G van Kroonenburgh; Patty J Nelemans; Petal A H M Wijnen; Marjolein Drent Journal: BMC Pulm Med Date: 2012-09-14 Impact factor: 3.317
Authors: Wilhelmina Maria Cornelia Timmermans; Jan Alexander Michael van Laar; Petrus Martinus van Hagen; Menno Cornelis van Zelm Journal: Clin Transl Immunology Date: 2016-12-16